These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694 [TBL] [Abstract][Full Text] [Related]
5. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age. Cieslak CM Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539 [TBL] [Abstract][Full Text] [Related]
6. Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain. Pérez Martín JJ; Zornoza Moreno M Hum Vaccin Immunother; 2024 Dec; 20(1):2365804. PubMed ID: 39137331 [TBL] [Abstract][Full Text] [Related]
7. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312 [TBL] [Abstract][Full Text] [Related]
8. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T; N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726 [TBL] [Abstract][Full Text] [Related]
9. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN; N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500 [TBL] [Abstract][Full Text] [Related]
10. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A Front Immunol; 2021; 12():708939. PubMed ID: 34456918 [TBL] [Abstract][Full Text] [Related]
11. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Bergeron HC; Tripp RA Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485 [TBL] [Abstract][Full Text] [Related]
12. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207 [TBL] [Abstract][Full Text] [Related]
13. RSV Prevention in All Infants: Which Is the Most Preferable Strategy? Esposito S; Abu Raya B; Baraldi E; Flanagan K; Martinon Torres F; Tsolia M; Zielen S Front Immunol; 2022; 13():880368. PubMed ID: 35572550 [TBL] [Abstract][Full Text] [Related]
14. Balanced on the Biggest Wave: Nirsevimab for Newborns. McPherson C; Lockowitz CR; Newland JG Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778 [TBL] [Abstract][Full Text] [Related]
15. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales. Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884 [TBL] [Abstract][Full Text] [Related]
16. Impact of universal immunization program with monoclonal antibody nirsevimab on reducing the burden of serious bronchiolitis that need pediatric intensive care. Alejandre C; Penela-Sánchez D; Alsina J; Agüera M; Soler A; Moussalam S; Muñoz-Almagro C; Brotons P; Cambra FJ; Forner OR; Balaguer M; Launes C; Jordan I Eur J Pediatr; 2024 Sep; 183(9):3897-3904. PubMed ID: 38910199 [TBL] [Abstract][Full Text] [Related]
17. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. Narayan O; Bentley A; Mowbray K; Hermansson M; Pivonka D; Kemadjou EN; Belsey J J Med Econ; 2020 Dec; 23(12):1640-1652. PubMed ID: 33107769 [TBL] [Abstract][Full Text] [Related]
18. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Martinón-Torres F; Mirás-Carballal S; Durán-Parrondo C Euro Surveill; 2023 Dec; 28(49):. PubMed ID: 38062942 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29-34 6/7 weeks' gestation in the United States. Yu T; Padula WV; Yieh L; Gong CL Pediatr Neonatol; 2024 Mar; 65(2):152-158. PubMed ID: 37758594 [TBL] [Abstract][Full Text] [Related]